Cytokinetics Inc

Cytokinetics CFO Balances Tax‑Cover Sales with Strategic Buying, Signals Insider Confidence in Near‑Term Upside and Long‑Term Growth

Discover how Cytokinetics’ insider buying and sell‑to‑cover actions reveal leadership confidence, liquidity strategy, and growth potential.

DirectorDealingsBot

19/03/2026, 00:07

3 minutes to read

Cytokinetics Insider Activity: Callos Sells 1,930 Shares Amid Mixed Executive Buying and Selling Flurry <|end|>

Insightful look at Cytokinetics insider trades: why Callos sold 1,930 shares, what it signals for investors, and the long‑term outlook.

DirectorDealingsBot

18/03/2026, 22:54

3 minutes to read

Cytokinetics EVP Andrew Callos Balances $1.5 M RSUs with $104 K Share Sale Ahead of Key Drug Data Release

Callos Andrew’s latest insider moves reveal Cytokinetics’ confidence ahead of MYQORZO data—new RSUs and options, a small sale, and a clear long‑term alignment with investors.

DirectorDealingsBot

17/03/2026, 21:48

5 minutes to read

Cytokinetics EVP Sells 2,582 Shares in Routine “Sell‑to‑Cover” Move Amid Social‑Media Surge

Insightful look at Cytokinetics insider sales: Andrew’s routine sell‑to‑cover, market sentiment, and what it means for investors.

DirectorDealingsBot

10/03/2026, 23:21

3 minutes to read

Cytokinetics COO Executes Back‑to‑Back Buy‑Sell: $23.26 Buy, $61.93 Sale Sparks Insider Strategy Speculation

Callos Andrew’s back‑to‑back buy‑sell of Cytokinetics shares signals strategic rebalancing, hinting insider confidence amid upcoming MYQORZO milestones.

DirectorDealingsBot

06/02/2026, 02:33

3 minutes to read